Skip to content

High-quality evidence, generated faster.

HEviAI builds AI-powered tools for HEOR, evidence synthesis and market access. AI takes on the repetitive work, so your team can focus on the scientific judgement that matters.

Evidence workspaceIllustrative

Search strategy

QuickSLR · AI working

10%

Activity

  • Building search strings from PICOS criteria
Human review on every suggestion Audit trail recorded

Evidence generation is getting harder every year.

Teams are expected to deliver more in less time, without compromising the rigour and transparency that payers and HTA bodies demand.

  • Growing literature volumes

    More publications to search, screen and extract with every review.

  • Evolving HTA requirements

    New methods guidance and processes, including EU Joint Clinical Assessment.

  • Tighter timelines

    Less time between evidence and submission, with the same scrutiny.

HEviAI combines advanced AI with deep HEOR expertise, so researchers spend less time on repetitive tasks and more time on the judgement that truly matters.

Two products. Two of the most critical steps in HEOR.

Gathering the evidence, and turning it into the inputs that drive economic models and reimbursement decisions.

AI-assisted literature reviews

QuickSLR

Systematic and targeted reviews, without the bottlenecks.

QuickSLR supports every stage of the review, from search strategy and screening to data extraction and quality appraisal. Every AI suggestion is reviewable by your experts, with the documentation HTA bodies expect.

  • Search strategy support
  • AI title, abstract and full-text screening
  • Data extraction with links to the source
  • Quality appraisal
  • Human review of every AI suggestion
  • Full audit trail and PRISMA reporting
QuickSLR · Title and abstract screeningIllustrative
Record 413 of 1,000 Dual screening on

An investigational therapy versus standard of care in previously treated advanced disease: a randomised phase III trial

Methods: Adults with previously treated advanced disease were randomised 1:1 to the investigational therapy or standard of care. The primary endpoint was overall survival; progression-free survival and quality of life were secondary endpoints.

PopulationInterventionComparatorOutcomesStudy design

AI suggests: Include

94% confidence

3 supporting quotes

Reviewer confirmed: Included

Logged to audit trail
AI-assisted survival analysis

DigiSurv

From published KM curve to model-ready inputs.

DigiSurv digitises published Kaplan–Meier curves, reconstructs individual patient data, and supports survival model fitting and extrapolation in line with HTA methodological guidance. A time-consuming, error-prone task becomes fast, reproducible and fully traceable.

  • AI digitisation of KM curves
  • Individual patient data reconstruction
  • Parametric and flexible model fitting
  • Extrapolation aligned with HTA guidance
  • Reproducible, traceable workflow
  • Export for economic models
DigiSurv · Overall survival, Figure 2Illustrative
012243648600.00.51.0MonthsData cut-off
IPD reconstructed

From evidence to decision, connected.

QuickSLR gathers the evidence. DigiSurv turns it into the inputs economic models need. Your team stays in control at every step.

  1. Step 1

    Published literature

    Databases, trials and conference abstracts

  2. Step 2

    QuickSLR

    Search, screen, extract, appraise

  3. Step 3

    DigiSurv

    Digitise, reconstruct, fit, extrapolate

  4. Step 4

    Models and submissions

    Cost-effectiveness, budget impact, HTA dossiers

What we build

AI-powered tools across the evidence lifecycle, designed with HEOR teams and the HTA bodies they answer to in mind.

  • AI-assisted literature reviews

    Searching, screening, data extraction and quality appraisal for systematic and targeted reviews, with every AI suggestion reviewable by human experts.

  • Evidence synthesis and analytics

    Support for meta-analyses, network meta-analyses and living reviews that update as new evidence emerges.

  • Health economic modelling support

    Build, validate and adapt cost-effectiveness and budget impact models more efficiently.

  • Value and HTA documentation

    AI-assisted drafting for global value dossiers, HTA submissions and EU Joint Clinical Assessment preparation.

  • Real-world evidence insights

    Turn complex real-world data into structured, decision-ready findings.

Our principles

AI accelerates the work. Experts make the decisions.

AI suggests

Screening, extraction, digitisation

Expert reviews

Accept, edit or reject

Approved and logged

Every decision on the record

  • Human-in-the-loop by design

    Every output can be reviewed, edited and approved by your team.

  • Transparent and auditable

    Full traceability from source to output, so every data point can be verified and every decision documented for HTA and regulatory scrutiny.

  • Built by HEOR experts, for HEOR experts

    Shaped by people who understand evidence synthesis and market access from the inside, not just the technology.

  • Secure and compliant

    Data protection and responsible AI practices are built into our platform from the ground up.

Our vision

We envision a future where high-quality evidence is generated faster, decisions are made with greater confidence, and effective treatments reach patients sooner.

HEviAI exists to make that future possible, by giving evidence teams the intelligent tools they deserve.

Who we work with

  • Pharmaceutical companies
  • Biotechnology companies
  • Medical device companies
  • HEOR consultancies

What we build with

  • Agentic AI
  • AI agents
  • Python
  • R
  • Shiny
  • C++

Let’s build the future of evidence together.

Book a demo of QuickSLR or DigiSurv, or tell us about the evidence challenge your team is facing.